Evidence map›Paper›PMID 30298467›Full record

GuidelineClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients.

R Vera, M J Otero, F Ayala de la Peña, C González-Pérez, Á Peñuelas, J M Sepúlveda, N Quer, N Doménech-Climent, J A Virizuela, P Beorlegui and 1 more

Abstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

R VeraServicio de Oncología Médica, Complejo Hospitalario de Navarra, Calle Irunlarrea, 3, 31008, Pamplona, Navarra, Spain. ruth.vera.garcia@cfnavarra.es.ORCID http://orcid.org/0000-0003-0156-0029
M J OteroInstituto para el Uso Seguro de los Medicamentos (ISMP-España), Servicio de Farmacia Hospitalaria, Hospital Universitario de Salamanca, Salamanca, Spain.
F Ayala de la PeñaServicio de Hematología y Oncología Médica, Hospital General Universitario Morales Meseguer, Murcia, Spain.
C González-PérezServicio de Farmacia Hospitalaria, Hospital Clínico San Carlos, Madrid, Spain.
Á PeñuelasCoordinadora de Enfermería Oncológica, Hospital Universitari Vall d'Hebron, Vall d'Hebron Instituto de Oncología, Barcelona, Spain.
J M SepúlvedaServicio de Oncología Médica, Hospital Universitario Doce de Octubre, Madrid, Spain.
N QuerServicio de Farmacia Hospitalaria, Instituto Catalán de Oncología, Barcelona, Spain.
N Doménech-ClimentAdjunta de Enfermería, Hospital Virgen de los Lirios, Alcoy, Spain.
J A VirizuelaServicio de Oncología Médica, Hospital Universitario Virgen Macarena, Seville, Spain.
P BeorleguiEnfermería Clínica Avanzada, Clínica Universitaria de Navarra, Pamplona, Spain.
M Q GorgasServicio de Farmacia Hospitalaria, Hospital Universitario Vall d'Hebron, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo define recommendations that permit safe management of antineoplastic medication, minimise medication errors and improve the safety of cancer patients undergoing treatment.

methodsBy reviewing the literature and consulting the websites of various health organisations and agencies, an expert committee from the Spanish Society of Hospital Pharmacy and the Spanish Society of Medical Oncology defined a set of safe practices covering all stages of providing cancer therapy to patients. The Spanish Society of Oncology Nursing revised and endorsed the final list.

resultsIn total, 68 recommendations arranged in five sections were defined. They include issues concerning the training of health professionals, the technological resources needed, treatment planning, informing the patient and his/her family, the processes of prescribing, preparing, dispensing and administering cancer therapy (orally, parenterally or intrathecally), assessing patient adherence and treatment toxicity.

conclusionsIt is essential for healthcare establishments to implement specific measures designed to prevent medication errors, in order to ensure the safety of cancer patients treated with antineoplastic medication.

Indexed as

Antineoplastic AgentsHumansMedical OncologyMedication ErrorsMedication Therapy ManagementNeoplasmsOncology NursingPatient SafetyPharmacy Service, HospitalSpainAntineoplastic AgentsAntineoplastic agentsMedication errorsPatient safetyPrevention and controlSafety management organisation and administration

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.